Deerfield Management Company, L.P. (Series C) Biocryst Pharmaceuticals Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 12,169,000 shares of BCRX stock, worth $86.2 Million. This represents 1.72% of its overall portfolio holdings.
Number of Shares
12,169,000
Previous 4,692,000
159.36%
Holding current value
$86.2 Million
Previous $42 Million
119.7%
% of portfolio
1.72%
Previous 0.97%
Shares
28 transactions
Others Institutions Holding BCRX
# of Institutions
312Shares Held
200MCall Options Held
640KPut Options Held
507K-
Vanguard Group Inc Valley Forge, PA21.8MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$141 Million0.0% of portfolio
-
State Street Corp Boston, MA9.81MShares$69.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.39MShares$66.5 Million6.02% of portfolio
-
Ubs Group Ag5.97MShares$42.3 Million0.01% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.32B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...